Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial 

Dupixent^® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial 

• First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo
• First and only biologic to show rapid and significant improvement in lung function (160 mL in FEV₁) compared to placebo (77 mL in FEV₁)
• First and only biologic to demonstrate significant improvements in quality of life and respiratory symptoms
• COPD is the third leading cause of death worldwide with no new treatment approaches approved in more than a decade; trial enrolled patients with moderate to severe disease and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells/μL)
• COPD is the seventh disease in which Dupixent has shown positive pivotal results, confirming the key role of IL-4 and…